Quick read · 4 min
You didn't pre-treat. Here's what to do now.
The realistic catch-up plan when pollen is already here
In short
The realistic catch-up plan when pollen is already here
The ideal plan starts six weeks before pollen rises. The actual situation, for a lot of people, is that you remember to think about hayfever the morning your eyes won't stop streaming.
This is the realistic catch-up plan. It won't recover the early-season buffer you'd have had — that's gone — but it can meaningfully change the next two to three weeks.
The first 48 hours
The priority is to load the medications that take time to work, while doing everything you can to reduce the load on the system right now.
Start the nasal spray today
Even though intranasal corticosteroids take 2–3 weeks to reach full effect, they start working from day one. There's no benefit to waiting.
- Pick a daily time you'll remember — pair it with brushing your teeth.
- Don't stop because you don't feel a difference in the first few days. The effect builds.
- If you find the spray drips into your throat, you're tilting too far back.
Start the daily antihistamine
Take a second-generation antihistamine (cetirizine, loratadine, fexofenadine, or bilastine) today, then daily. Peak plasma in 1–3 hours; meaningful tissue saturation across 2–3 days of consistent dosing.
Don't switch to reactive dosing ("I'll take one when I feel bad"). That's the pattern that fails — by the time you feel bad, histamine is already bound to your receptors and the drug can only block the next molecule, not the current symptoms.
Saline rinse twice a day
This is the fastest-acting intervention you have. 28% symptom reduction in pooled trials, no side effects, costs almost nothing. Morning and evening, high-volume bottle or neti pot, sterile or pre-boiled water.
Antihistamine eye drops if eyes are involved
Don't wait to "see if the tablet handles it" — it likely won't, because oral antihistamines reach the conjunctiva poorly. Olopatadine or azelastine drops act within minutes.
Days 3–7: Bedding in
By the end of the first week:
- The antihistamine is at full tissue saturation.
- The nasal spray is roughly a third of the way to full effect.
- The saline rinse has cleared a meaningful amount of accumulated load.
You should be feeling notably better than day one. Not "fixed" — better. If you're not, that's a sign to check:
- Are you actually taking everything daily? Adherence drops fast once people feel improvement.
- Is your antihistamine the right one? If you're foggy on cetirizine, switch to fexofenadine or bilastine.
- Is the spray reaching the right place? Watch a technique video — most people aim it wrong.
This is also the right time to start the bedroom basics if you haven't:
- Windows closed from sunrise.
- Air purifier in the bedroom.
- Evening shower with hair wash.
- Bedding wash at 60°C.
Days 7–21: Reaching full protection
By three weeks of daily INCS, you're approaching full anti-inflammatory effect. This is when people who started late often feel their best in the season — better, sometimes, than if they'd half-heartedly pre-treated.
The temptation now is to dial things back because you feel okay. Don't. The treatment is what's keeping you okay. Stop and you'll feel why within 3–5 days.
What to expect honestly
A catch-up plan is not as good as a proper pre-season plan. Specifically:
- The first 10–14 days will be harder than they would have been.
- Sleep will likely be more disrupted in the catch-up window.
- You may need eye drops and second-rinse "bad day" add-ons more often than someone who started early.
By week 3, the gap closes substantially. By week 5, you're functionally in the same place. The cost of starting late is mostly paid in the first fortnight.
What not to do
- Don't use a first-generation antihistamine to "hit it hard." The sedation and cognitive impairment compound, and the symptom relief isn't better than second-generation.
- Don't start a daily decongestant nasal spray. Rebound congestion (rhinitis medicamentosa) sets in after about five days of continuous use, and you'll be in a worse position.
- Don't go to oral steroids first. They work, but they have meaningful systemic effects and are reserved for severe cases under clinical supervision. Talk to a GP if the standard regimen isn't enough.
When to escalate to a specialist
Most hayfever is well-managed by the routine above — saline rinse, daily INCS, daily antihistamine, eye drops as needed, the bedroom basics. But there's a clear threshold at which the right next step is a specialist allergy clinic rather than another tweak of the same regimen.
UK clinical practice — based on the ARIA framework adapted into local pathways — points to specialist referral when:
- You have moderate-to-severe symptoms (sleep disturbance, work or activity impairment, or troublesome symptoms) that remain uncontrolled after 2–4 weeks of correctly-used daily intranasal corticosteroid plus a non-sedating oral antihistamine. A simple way to put this: if your overall symptom score sits at 5 out of 10 or higher despite doing the routine properly, that's the threshold.
- You're needing repeated oral steroid courses to get through a season. This is an absolute indication — chronic oral steroid use is not a sustainable plan.
- You've had two or more debilitating pollen seasons despite optimal medication. You may be eligible for allergen immunotherapy (sublingual tablets or subcutaneous injections that desensitise your immune system over 3 years), which is provided through specialist services.
- You have multisystem atopy with poorly-controlled asthma alongside the hayfever — both need looking at together.
- There's diagnostic uncertainty, suspected occupational rhinitis, or red-flag features like unilateral nasal obstruction, blood-stained discharge, or facial pain. These need ENT rather than allergy referral.
The route
Where it exists in your area, the first stop is a GP with Special Interest (GPwSI) in allergy running a community clinic — faster access than hospital and sufficient for most referrals. Where it doesn't, your GP refers directly to a hospital-based specialist allergy clinic. ENT goes through a separate pathway for structural problems.
Waiting times vary considerably by region. If your symptoms are functional-life-affecting, ask about that explicitly — it can change the routing.
A note on what the referral threshold isn't: it isn't a numeric line in a national guideline. The 5/10 VAS figure and the 2–4 week trial period are widely-used expert-consensus benchmarks rather than RCT-derived cut-offs. The decision is fundamentally clinical — your GP weighing your symptom impact against what you've already tried — and it's reasonable to push the conversation if you feel the routine isn't enough.
Make next year easier than this one
Set a calendar reminder right now for six weeks before this season started. That's your start date next year. The single intervention with the highest payoff in hayfever management is setting that reminder while the memory of this year is fresh.
A catch-up plan works. It's not optimal, but it's effective, and the gap between catch-up and pre-season closes faster than people expect once the treatments are properly loaded.
Terms in this article
- Conjunctiva
- The thin, transparent membrane covering the white of the eye and the inside of the eyelid.It is densely packed with mast cells, which is why hayfever hits the eyes so hard.
The evidence
What the research actually says
Each answer below is drawn from a graded research review. Confidence reflects the strength of the underlying evidence, not how confident we feel about it.
Can early-season treatment reduce severity?
Early-season and pre-seasonal treatment of allergic rhinitis is supported by evidence across multiple modalities, including intranasal corticosteroids (INCS), sublingual immunotherapy (SLIT), subcutaneous immunotherapy (SCIT), and omalizumab, all demonstrating reduced symptom severity compared to in-season or reactive treatment. A prospective RCT found preseasonal omalizumab (300mg ~2 weeks before pollen season) superior to standard medication, while pre- and co-seasonal SLIT regimens show consistent benefit in pollen-induced rhinoconjunctivitis. Early antihistamine initiation (e.g., fexofenadine before peak pollen) also showed reduced severity compared to delayed treatment initiation.
How it works
Pre-seasonal treatment allows anti-inflammatory and immunomodulatory effects to establish before allergen exposure peaks; INCS require 2-4 weeks to maximally downregulate inflammatory cells and vascular permeability, while immunotherapy progressively shifts immune responses from Th2-dominant toward tolerance, reducing IgE-mediated mast cell and basophil activation during the subsequent pollen season.
Confidence: moderate
What are the main reasons hayfever sufferers stop or forget prophylactic treatment?
Adherence to prophylactic allergic rhinitis treatments is consistently poor, with high adherence achieved in only 19–50% of cases depending on medication class and measurement method. The primary reasons patients stop or forget prophylactic treatment include forgetfulness (occurring 1–5 times per 30 days), symptom-driven use (approximately 20% of patients use medication only when symptomatic), corticosteroid phobia regarding intranasal corticosteroids, perceived lack of benefit, and increasing non-adherence with longer disease duration. For allergen immunotherapy, the barriers are compounded by the multi-year treatment commitment, with most patients discontinuing within the first year.
How it works
Allergic rhinitis symptoms fluctuate seasonally and episodically, which undermines patients' perceived need for daily prophylactic dosing during asymptomatic periods, creating a mismatch between the continuous-use requirement of preventive therapy and patients' symptom-contingent health behaviour. Corticosteroid phobia likely reflects misattribution of systemic steroid risks to low-bioavailability intranasal formulations, while caregiving demands and complex regimens deplete the cognitive resources needed for habitual medication routines.
Confidence: moderate
How quickly do different antihistamines reach peak effectiveness after dosing?
Antihistamines generally reach peak plasma concentrations within 1-3 hours after oral administration, though there is meaningful variation between agents. Second-generation antihistamines like cetirizine reach Tmax rapidly (0.5-1 hour), while others such as bilastine (1.1-1.4 hours), loratadine, and fexofenadine follow at 1-3 hours; first-generation agents are similarly absorbed quickly but their longer half-lives (e.g., ~20 hours for chlorpheniramine) can prolong CNS effects. Clinical onset of symptom relief, as measured by histamine wheal-and-flare suppression, broadly aligns with these pharmacokinetic profiles, with meaningful antihistaminic activity typically observed within 1-2 hours post-dose.
How it works
H1-receptor antagonists are absorbed through the gastrointestinal tract and competitively block peripheral and, for first-generation agents, central H1 receptors; peak receptor occupancy and pharmacodynamic effect correlate broadly with peak plasma concentrations, though tissue distribution and receptor binding kinetics can create a slight lag between Tmax and maximal clinical effect. Second-generation agents generally have lower CNS penetration due to P-glycoprotein efflux and protein binding characteristics, confining their primary effects to peripheral H1 receptors.
Confidence: moderate
What is the mechanism of action of H1-receptor antagonists in allergic rhinitis?
H1-receptor antagonists act primarily as inverse agonists at H1-receptors on nerve endings, smooth muscle, and glandular cells, blocking histamine-mediated symptoms of allergic rhinitis such as pruritus, sneezing, rhinorrhea, and vasodilation. Beyond competitive histamine blockade, multiple studies indicate these agents possess additional anti-inflammatory and immunomodulatory properties, including suppression of Th2 cytokines (e.g., IL-4), modulation of CD4+ T lymphocyte subsets, and reduction of proinflammatory mediators such as IL-6 and TNF-α. Second-generation agents (e.g., cetirizine, loratadine, desloratadine, levocetirizine) deliver these effects with minimal CNS penetration compared to first-generation antihistamines.
How it works
Allergen cross-linking of IgE on mast cells and basophils triggers degranulation and histamine release; H1-antagonists function as inverse agonists by binding H1-receptors and suppressing both histamine-stimulated and constitutive receptor activity, thereby preventing downstream signaling cascades responsible for nasal inflammation. Additional immunomodulatory effects — including upregulation of regulatory T cells and inhibition of Th2-skewed cytokine production — may contribute to sustained clinical benefit beyond acute histamine blockade.
Confidence: high
Can nasal irrigation reduce allergen load?
Nasal irrigation with saline solutions effectively reduces allergen load in nasal passages through mechanical clearance, with a 2012 meta-analysis (Hermelingmeier et al.) demonstrating a 27.66% reduction in AR symptoms, 66% decrease in medication use, and 31.19% improvement in mucociliary clearance. Multiple RCTs and comparative studies confirm that nasal irrigation—particularly high-volume, low-pressure methods used 2–3 times daily—provides clinically meaningful symptom relief and, when combined with intranasal steroids, outperforms either treatment alone. High-volume irrigation (125–176 mL, 3x/day) in steroid-free AR patients has also been shown to prevent seasonal IgE elevation, suggesting direct attenuation of allergen-driven immune responses.
How it works
Saline irrigation mechanically dilutes and flushes allergens, inflammatory mediators, and mucus from nasal mucosa, preserving epithelial barrier integrity and limiting allergen penetration and subsequent IgE sensitization. Hypertonic solutions additionally reduce mucosal edema and restore impaired mucociliary clearance, further accelerating allergen removal from the nasal cavity.
Confidence: moderate
Does allergic conjunctivitis require different treatment than nasal allergy symptoms?
Allergic conjunctivitis (AC) frequently coexists with allergic rhinitis (AR) as part of 'allergic rhinoconjunctivitis,' but does require distinct and targeted treatment beyond systemic or intranasal therapies alone. While oral second-generation antihistamines and intranasal corticosteroids used for AR provide some benefit for ocular symptoms, topical ocular therapies—including ophthalmic antihistamines, mast cell stabilizers, and topical corticosteroids—are often necessary to adequately control AC symptoms. Ophthalmic antihistamines are at least as effective as oral antihistamines for ocular symptoms and offer faster local onset, supporting their use as an adjunct or alternative in patients with significant conjunctival involvement.
How it works
Both AR and AC share IgE-mediated mast cell activation and mucosal immune responses, but the conjunctival tissue has distinct local immunological dynamics, including direct allergen exposure and a unique tear film environment, that systemic or intranasal agents may not sufficiently address. A proposed nasal-ocular reflex pathway may also partially link nasal and ocular symptom generation, though local conjunctival treatment targets the tissue-specific inflammatory cascade more directly.
Confidence: moderate
Are intranasal steroids more effective than antihistamines?
Intranasal corticosteroids (INS) are consistently more effective than oral antihistamines for treating allergic rhinitis, particularly for nasal symptoms including congestion, rhinorrhea, sneezing, and nasal itching, as demonstrated across multiple systematic reviews and meta-analyses spanning 1998–2024. The 2024 Torres et al. meta-analysis of 35 RCTs found INS superior on Total Nasal Symptom Score (SMD -0.70) and quality of life measures (RQLQ mean difference -0.90) compared to oral antihistamines. Notably, ocular symptoms represent an exception where oral antihistamines perform comparably to INS, and intranasal antihistamines combined with INS outperform oral antihistamines combined with INS.
How it works
Intranasal corticosteroids act through direct topical anti-inflammatory effects on nasal mucosa, suppressing multiple inflammatory mediators (histamine, leukotrienes, cytokines) and reducing both early and late-phase allergic responses, thereby addressing the underlying mucosal inflammation rather than individual symptom pathways. Oral antihistamines selectively block H1-receptor mediated symptoms systemically but achieve limited local nasal concentrations and do not effectively counteract non-histamine inflammatory mediators, explaining their inferior efficacy for congestion in particular.
Confidence: high
References
- 1.10.1002/clt2.12094
- 2.10.1186/s13601-015-0061-z
- 3.10.15197/SABAD.4.1.12
- 4.10.5631/JIBIRIN.99.501
- 5.10.1111/j.1398-9995.2005.00790.x
- 6.Bender B. · 2015 · Motivating Patient Adherence to Allergic Rhinitis Treatments
- 7.Baiardini I, Novakova S, Mihaicuta S et al. · 2018 · Adherence to treatment in allergic respiratory diseases
- 8.10.1111/j.1365-2222.2012.04052.x
- 9.10.1002/lio2.986
- 10.Chen C, Wu R. · 2025 · Analysis of Influencing Factors on Medication Adherence in Patients with Allergic Rhinitis
- 11.10.2165/00003088-198510060-00002
- 12.10.1201/9780429276965-12
- 13.10.4103/0378-6323.42907
- 14.10.1016/S0002-9343(02)01436-5
- 15.Baroody F., Naclerio R. · 2000 · Antiallergic effects of H1-receptor antagonists
- 16.10.2165/00003495-200767180-00006
- 17.10.2174/156801405774330349
- 18.10.15649/2346075x.3651
- 19.Weiner JM, Abramson MJ, Puy RM · 1998 · Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials
- 20.Hermelingmeier KE, Weber RK, Hellmich M, et al. · 2012 · Nasal irrigation as an adjunctive treatment in allergic rhinitis: A systematic review and meta-analysis
- 21.10.18502/ijaai.v24i1.18016
- 22.10.1007/s00405-025-09392-y
- 23.10.18410/JEBMH/2017/578
- 24.10.30659/sainsmed.v14i1.31474
- 25.10.58347/tml.2025.1725a
- 26.Borges S, Pereira VA, Chang C · 2025 · Where eye meets body part 1: uniting allergy pathways in ocular and nasal disease - IgE on the offense
- 27.Iordache A, Borugă M, Mușat O · 2022 · Relationship between allergic rhinitis and allergic conjunctivitis (allergic rhinoconjunctivitis) - review
- 28.10.5124/jkma.2023.66.9.556
- 29.10.1111/j.1365-2222.2011.03835.x
- 30.10.1016/j.jaip.2024.09.001
- 31.Juel-Berg N, Darling P, Bolvig J et al. · 2017 · Intranasal Corticosteroids Compared with Oral Antihistamines in Allergic Rhinitis: A Systematic Review and Meta-Analysis
- 32.Sousa-Pinto B., Vieira R., Brozek J. et al. · 2024 · Intranasal antihistamines and corticosteroids in allergic rhinitis: A systematic review and meta-analysis
This article is general information about hayfever, not medical advice. It should not replace guidance from your GP, pharmacist or allergy specialist — particularly if you are pregnant, treating a child, or managing asthma alongside hayfever. Read our medical disclaimer.



